Reversing the Effects of 0.5% Bupivacaine

• Status: Completed
• Trial end date: 2019-09-15
• Target enrollment: 0
• Participant gender: All

Summary

Clinical trials have shown phentolamine mesylate (PM), brand name OraVerse, to be effective at reducing the amount of time to reversal of local anesthesia with different dental anesthetics. However, to date no study investigated the efficacy of phentolamine mesylate to reverse anesthesia induced with the use of Bupivacaine.

The objective of the proposed research is to conduct a pilot-scale randomized clinical trial evaluating the difference in time required for the return of normal soft-tissue sensation and function in participants who have received 0.5% Bupivacaine HCl, 1:200,000 epinephrine, followed by an injection with either 1) OraVerse (phentolamine mesylate) or 2) sterile physiological water (control).

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Dalhousie University
• Treatments: Bupivacaine; Phentolamine

Criteria

Inclusion Criteria:

• 18 years of age or older

• capable of providing informed consent

Exclusion Criteria:

• contra-indications for regular dental treatment

• medical history that contraindicates the use of epinephrine

• participant taken an opioid or an opioid like analgesic within 24 hours

• pregnant